SIGLEC1 and cancer: Its product, GM3, is a CD169/Siglec‐1 binding ligand, and GM3‐containing liposomes are incorporated by CD169+ MΦs [16], suggesting that ST3G5 in cancer cells affects the affinity of cExo to lymphoid tissues.